For One VC, Turning From Technology to Drug Discovery is Dumb | GenomeWeb

This clarification notes that Novartis did not acquire Vertex for $800 million, but rather entered into a collaboration with the company in May 2000 for the same dollar amount to "discover, develop, and commercialize small molecule drugs directed at targets in the kinase protein family."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.